IMUGENE LIMITED — Capital/Financing Update 2017

Dec 18, 2017

==> picture [175 x 58] intentionally omitted <==

19[th] December 2017

**ASX

Announcement**

**Rights

Issue Results & Shortfall Notification**

Imugene Limited (Company) refers to its 1 for 21 non-­‐renounceable pro-­‐rata rights issue (‘Rights Issue’) announced on 23 November 2017. The following notice is given in accordance with Appendix 7A of the ASX Listing Rules.

Pursuant to the Rights Issue the Company advises that it has received applications from Australian and New Zealand shareholders for 25,581,180 shares at $0.018 per share raising $460,351.29. The resulting shortfall from the Rights Issue is 87,265,108 shares, which the Company will allocate in accordance with the underwriting arrangements for the Rights Issue.

The issue of shares and attaching options pursuant to the Rights Issue and resulting shortfall is anticipated to be completed on Friday 22 December 2017.

Justyn Stedwell Company Secretary

IMUGENE LIMITED ACN 009 179 551 Telephone +61 3 9824 5254 Fax +61 3 9822 7735 Website www.imugene.com